A startling suggestion is buried in the fine print describing proposed changes for the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders — perhaps better known as the D.S.M. 5, the book that will set the new boundary between mental disorder and normality. If this suggestion is adopted, many people who experience completely normal grief could be mislabeled as having a psychiatric problem.
With drafts of the latest edition of the world’s leading psychiatry manual emerging, critics question the growing medicalisation of life’s problems. Over the past three decades, unhappiness has been redefined as depression, shyness has been reclassified as social anxiety disorder – even trivial complaints such as fussy eating are now being viewed through a psychiatric prism. Some of this is due to a single book, the Diagnostic and Statistical Manual , which critics claim is contributing to the ever-expanding empire of mental health. The next official edition of the DSM will be published in May 2013, but draft versions are currently doing the rounds.
The US Department of Justice is scrutinising payments by leading pharmaceuticals companies for hospitality, consultants, licensing agreements and charitable donations in markets around the world as part of a wide-ranging corruption probe. GlaxoSmithKline, Pfizer, Bristol-Myers Squibb and Eli Lilly, among others, have disclosed being contacted by the DoJ and Securities and Exchange Commission in connection with the investigation.
The suicide rate among military veterans has ballooned in recent years, in part because of overmedication of service members and a lack of support for veterans, advocates for treatment of Post Traumatic Stress Disorder said Thursday. Psychiatrists sometimes prescribe drugs as a cure without an actual understanding of what the drugs do, said Dr. Peter R. Breggin, a psychiatrist and author from Ithaca, N.Y.
The total worldwide market for antipsychotic drugs is expected to reach $19.6 billion in 2010. With continued market penetration into new diseases and price increases for currently marketed antipsychotics, this market is expected to grow to a high of $20.8 billion in 2011 and then hit a low of $14.4 billion in 2013, before resuming growth again to $14.8 billion in worldwide sales for 2014.
SHARE YOUR STORY/COMMENT: